HGH (Human Growth Hormone)
Recombinant 191-amino-acid polypeptide identical to endogenous pituitary growth hormone
- Class
- Hormone replacement
- Half-life
- ~2-3 hours
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Human clinical trials
Overview
Human growth hormone (HGH, somatotropin) is FDA-approved hormone replacement for children and adults with confirmed growth hormone deficiency — a rare disorder caused by pituitary failure from tumors, surgery, radiation, or congenital causes. It's the same 191-amino-acid molecule your pituitary makes naturally, produced via recombinant DNA. In people who actually lack GH, replacement is genuinely transformative: it corrects severe central obesity, restores lean mass, improves bone density, and reverses the cardiovascular decay that defines adult GH deficiency. Dosing is tightly managed via IGF-1 monitoring — you're aiming for the 50th percentile of age-adjusted normal, not supraphysiologic levels.
Outside of true deficiency, HGH is widely used off-label in athletic and anti-aging circles for its anabolic and lipolytic effects. The compound works by binding growth hormone receptors throughout the body, triggering JAK-STAT signaling that drives liver production of IGF-1 — which in turn promotes protein synthesis, collagen deposition, and fat breakdown. In the context of elite sport, it accelerates tendon and ligament repair, which is why it's been a mainstay of professional athletics despite being hard to detect. WADA has banned it since 1989, both in- and out-of-competition.
The safety picture splits sharply between replacement and pharmacologic use. In true GH deficiency, long-term safety data from over 15,000 patients show no increased cancer risk and manageable side effects when dosed appropriately. In healthy people taking supraphysiologic doses — the research-market scenario — the risks look different: glucose intolerance and insulin resistance are common, joint pain and edema are near-universal at higher doses, and there's a poorly quantified long-term cardiovascular risk. One widely cited trial in critically ill patients was stopped early because GH increased mortality via multiorgan failure and septic shock. It's not a casual compound.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Banned by WADA at all times (in- and out-of-competition) since 1989. Athletes in any WADA-compliant sport face strict liability for any detectable use or biomarker abnormality suggesting GH abuse.
- Contraindicated in active malignancy. GH stimulates cell proliferation; long-term safety data in adults with confirmed GH deficiency show no increased de novo cancer risk, but recurrence risk in people with prior cancer history is debated.
- Glucose intolerance and overt diabetes are common in pharmacologic (supraphysiologic) dosing. GH is a counter-regulatory hormone to insulin — it raises blood glucose and can unmask or worsen pre-diabetes.
+ 4 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching HGH (Human Growth Hormone).
- IGF-1 (serum) — primary titration marker for replacement dosing
- Fasting glucose and HbA1c — GH is counter-regulatory to insulin; impaired glucose tolerance is common
- Lipid panel — GH reduces LDL and increases lipolysis, but effects vary
- Thyroid function (TSH, free T4) — GH can unmask or worsen hypothyroidism
- Joint pain, peripheral edema — dose-dependent, usually reversible with dose reduction
- Body composition (DEXA) — lean mass and fat distribution changes are the point in deficiency treatment
Frequently asked questions
What is HGH (Human Growth Hormone)?
Recombinant 191-amino-acid polypeptide identical to endogenous pituitary growth hormone. Human growth hormone (HGH, somatotropin) is FDA-approved hormone replacement for children and adults with confirmed growth hormone deficiency — a rare disorder caused by pituitary failure from tumors, surgery, radiation, or congenital causes. It's the same 191-amino-acid molecule your pituitary makes naturally, produced via recombinant DNA. In people who actually lack GH, replacement is genuinely transformative: it corrects severe central obesity, restores lean mass, improves bone density, and reverses the cardiovascular decay that defines adult GH deficiency. Dosing is tightly managed via IGF-1 monitoring — you're aiming for the 50th percentile of age-adjusted normal, not supraphysiologic levels.
How is HGH (Human Growth Hormone) administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of HGH (Human Growth Hormone)?
~2-3 hours — Short plasma half-life but effects persist via IGF-1 induction lasting days.
Is HGH (Human Growth Hormone) approved for human use?
HGH (Human Growth Hormone) is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for HGH (Human Growth Hormone)?
Evidence tier: Human clinical trials. FDA first approved recombinant GH (somatropin) in 1985 for pediatric GH deficiency; adult GH deficiency was added as an indication in the 1990s. Multiple biosimilar and branded versions now exist.
What is commonly monitored when researching HGH (Human Growth Hormone)?
Commonly tracked markers + signals: IGF-1 (serum) — primary titration marker for replacement dosing, Fasting glucose and HbA1c — GH is counter-regulatory to insulin; impaired glucose tolerance is common, Lipid panel — GH reduces LDL and increases lipolysis, but effects vary, Thyroid function (TSH, free T4) — GH can unmask or worsen hypothyroidism, Joint pain, peripheral edema — dose-dependent, usually reversible with dose reduction, Body composition (DEXA) — lean mass and fat distribution changes are the point in deficiency treatment.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.